Risk Factors and Machine Learning Model for Beta-Lactam Drugs Related Acute Kidney Injury

NCT05533606 | Completed

• 1 other identifier: LCYY-LX-20220103
• Study Type: observational
• Target: 19,000
• Locations: 1 country
• Sites: 1

Brief Summary

Acute kidney injury (AKI), also known as acute kidney failure (ARF), is a common and complex kidney disease in clinic and an important factor related to poor prognosis of patients in clinic. In the present study, a single-center retrospective study was conducted in our center. The clinical data of hospitalized patients received β-Lactam drugs from January 2018 to December 2020 was retrospectively analyzed. The multiple logistic regression analysis suggested that complicated with hypertension, anemia, pneumonia, shock, sepsis, heart failure, combined use of proton pump inhibitors (PPI), angiotensin-converting enzyme inhibitor (ACEI), angiotensin Ⅱ receptor antagonist (ARB) were independent risk factors for AKI related to β-Lactam drugs. In clinical practice, patients with acute kidney injury risk factors should be closely monitored for changes in their blood creatinine and urine output to avoid acute kidney injury. For patients who have suffered from acute kidney injury, the cause should be removed in time and corresponding symptomatic treatment should be given.

Conditions

Acute Kidney Injury; Beta-Lactam Antibiotic Toxicity (Diagnosis)

Keywords

Beta-Lactam drugs; Acute kidney injury; Pharmacoepidemiology; Miss diagnosis; Risk factors; Logic regression

Outcome Measures

Primary Outcomes (1)

• The incidence of acute kidney injury in hospitalized patients treated with β-lactam drugs

  To analyze the incidence of acute kidney injury in hospitalized patients after using β-lactam drugs and to build a prediction model.

  Through study completion，up to half a year.

Study Arms (2)

AKI Group

Drug: Beta-Lactam Drugs

Non-AKI Group

Drug: Beta-Lactam Drugs

Interventions

Beta-Lactam Drugs DRUG

During hospitalization，patients used Beta-Lactam drugs.

AKI Group; Non-AKI Group

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The patients were included if received treatment with β-lactam drugs and discharged from the hospital between January 1, 2018 and December 31, 2020

You may qualify if:

• All inpatients who used β-lactam drugs during hospitalization
• Hospital stay ≥ 48h
• Age ≥18 years
• There are two or more blood creatinine tests during hospitalization

You may not qualify if:

• Hospital stay \< 48h
• Age \<18 years
• Glomerular filtration rate (GFR)\< 30ml/min/1.73m2 within 48 hours after admission
• AKI was diagnosed on admission
• Less than two Scr test results during hospitalization
• The Scr values were always lower than 40 μmol/L during hospitalization
• Cases with incomplete medical history information

Sponsors & Collaborators

• Qianfoshan Hospital: lead

Study Sites (1)

Xiao Li，MD

Jinan, Shandong, 250014, China

Location

MeSH Terms

Conditions

Acute Kidney Injury; Disease

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate professor of pharmacy

Study Record Dates

• First Submitted: September 2, 2022
• First Posted: September 9, 2022
• Study Start: July 1, 2022
• Primary Completion: June 30, 2023
• Study Completion: June 30, 2023
• Last Updated: November 18, 2023

Record last verified: 2023-11

Locations

CN (1)